- Policy
- Yoon Seok Yeol's generation
- by Lee, Jeong-Hwan Mar 13, 2022 08:03pm
- Yoon Seok-yeol, the power of the people, was elected in the 20th presidential election, signaling significant changes in the health care and pharmaceutical bio industries as a whole. Some keywords that are drawing attention right now are "promoting remote non-face-to-face treatment" and "the establishment of a pharmaceutical bio-control to
- Policy
- Omicron's fatality rate is at the level of flu
- by Lee, Jeong-Hwan Mar 10, 2022 05:53am
- The quarantine authorities analyzed that if the COVID-19 vaccine is completed up to the third round, the fatality rate of Omicron mutation will be 0.07%, which is similar to that of the seasonal flu fatality rate (0.05 to 0.1%). In particular, the fatality rate for those under the age of 60 who completed the third vaccination was 0%, while
- Policy
- Finding ways to utilize the Patent-approval linkage system
- by Lee, Hye-Kyung Mar 10, 2022 05:53am
- The MFDS plans to prepare a collection of data so that domestic pharmaceutical companies can pioneer the Chinese pharmaceutical market by utilizing the Patent-approval linkage system within the first half of this year. The MFDS recently announced research services for "Overseas the Patent-approval Linkage System Survey and Domestic Impact Ana
- Policy
- The fatality rate of Omicron is low
- by Lee, Jeong-Hwan Mar 8, 2022 06:08am
- The quarantine authorities announced a full-fledged easing of distancing, saying that it is becoming clearer that the COVID-19 Omicron mutation has a lower severity and fatality rate than the delta mutation. From the 5th to the 20th, the 22 o'clock operating hours limit, which will be applied to groups 1, 2, and 3, will be increased by 1 hour
- Policy
- DREC rejects reimb of neurofibromatosis drug ‘Koselugo'
- by Lee, Tak-Sun Mar 8, 2022 06:08am
- The new neurofibromatosis drug ‘Koselugo (selumetinib),’ failed to receive reimbursement benefits in Korea. The Health Insurance Review and Assessment Service decided the drug as a ‘non-benefit' after deliberation on the adequacy of providing medical benefit for the drug at the 3rd Drug Reimbursement Evaluation Committee that was held thi
- Policy
- Brukinsa was approved using phase 2 data on MCL indications
- by Lee, Hye-Kyung Mar 4, 2022 05:57am
- Brukinsa 80mg (Zanubrutinib), the first new drug in Korea by Chinese pharmaceutical company Beijing, has secured MCL indications only with therapeutic clinical trial data (phase 2). This is because there was an expert opinion that according to Article 7, No. 6 of the Regulations on Item Permission, Report, and Review of Medicines, it could r
- Policy
- Janumet's salt change consigned drug have been approved for
- by Lee, Hye-Kyung Mar 4, 2022 05:57am
- A large number of Janumet's salt change combination, which is commissioned and manufactured by Daewon Pharmaceutical, have been approved for items. The MFDS applied for a diabetes complex by Jin Yang, Young Poong, Withus, and Neo Bio Korea Pharm on the 2nd. 8 items of Sitaglipin HCl+Metformin and Colloidal Silicon Dioxide have been approve
- Policy
- Ahn Cheol Soo, promised for Vaccine Sovereignty
- by Lee, Jeong-Hwan Mar 3, 2022 06:00am
- Like other party candidates, the presidential candidate of the People's Party Ahn Cheol Soo also put securing vaccine sovereignty and fostering the pharmaceutical bio-industry at the forefront of health care pledges. It also announced specific pledges such as half-price hair loss drugs, free vaccination against rotavirus in newborns, supp
- Policy
- To establish a pharmaceutical bio-innovation committee
- by Lee, Jeong-Hwan Mar 3, 2022 06:00am
- Yoon Suk-youl, presidential candidate for the presidential election, pledged to establish a "pharmaceutical bio-innovation committee" directly under the Prime Minister, while creating an ecosystem that can establish sovereignty in pharmaceutical bio and foster key talents and jobs in the pharmaceutical bio industry. It is said that it will ov
- Policy
- Negotiations with NHIS on Actemra have been completed
- by Lee, Tak-Sun Mar 2, 2022 05:54am
- Actemra (Tocilizumab), a treatment for rheumatoid arthritis by JW Pharma, has been officially recognized as a treatment for COVID-19 in Korea. The drug, which has been used in patients with severe COVID-19 for purposes other than permission, will also be covered by health insurance benefits from March. On the 24th, the MOHW announced that
